Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
2.870
+0.050 (1.77%)
At close: Dec 24, 2025, 1:00 PM EST
2.890
+0.020 (0.70%)
After-hours: Dec 24, 2025, 4:59 PM EST
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 11 analysts that cover Iovance Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $10.45, which forecasts a 264.11% increase in the stock price over the next year. The lowest target is $2.00 and the highest is $20.
Price Target: $10.45 (+264.11%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $9 → $10 | Buy | Maintains | $9 → $10 | +248.43% | Dec 17, 2025 |
| Barclays | Barclays | Buy Maintains $4 → $9 | Buy | Maintains | $4 → $9 | +213.59% | Nov 24, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $20 → $17 | Strong Buy | Maintains | $20 → $17 | +492.33% | Nov 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $9 | Strong Buy | Maintains | $20 → $9 | +213.59% | Oct 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +596.86% | Aug 19, 2025 |
Financial Forecast
Revenue This Year
263.68M
from 164.07M
Increased by 60.71%
Revenue Next Year
420.61M
from 263.68M
Increased by 59.52%
EPS This Year
-1.08
from -1.28
EPS Next Year
-0.59
from -1.08
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 283.5M | 567.4M | ||||
| Avg | 263.7M | 420.6M | ||||
| Low | 246.0M | 333.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 72.8% | 115.2% | ||||
| Avg | 60.7% | 59.5% | ||||
| Low | 49.9% | 26.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.87 | -0.40 | ||||
| Avg | -1.08 | -0.59 | ||||
| Low | -1.13 | -1.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.